July 3, 2017
“We are concerned that this ICER report and the timing of its publication may increase the barriers between patients and effective treatments, even for those whom anabolic therapies are the only remaining treatment option.” - Dr. Benjamin Leder, ASBMR
ASBMR Professional Practice Committee Chair, Benjamin Leder, MD, testified on June 30, 2017 at a public meeting of the California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), to discuss concerns about a new report on the comparative effectiveness and value of anabolic therapies for osteoporosis in postmenopausal women. Other ASBMR members who testified or participated in the Policy Roundtable discussion included: Robin K. Dore, MD, Matthew Drake, MD, PhD, Stuart L. Silverman, MD, FACP, FACR and Deborah M. Kado, MD, MS
ICER’s report includes a systematic review of the published evidence as well as an economic analysis that examines the cost-effectiveness and budget impact of anabolic therapies for osteoporosis. The report was the basis for deliberation and discussion at the public meeting, where the CTAF panel voted on key questions raised in the reports, and a policy roundtable discussed evidence-based practice and policy. The final ICER report will be release on July 14.
View ASBMR Oral Testimony